Progressive supranuclear palsy (PSP) is an aggressive neurodegenerative disorder for which there is currently no approved treatment or cure. As a pure tauopathy and orphan disease, it has attracted industry attention as a promising market opportunity and important steppingstone to new therapies for Alzheimer's and corticobasal degeneration (CBD).

The PSP Research Roundtable is an industry led pre-competitive alliance involving selected industry leaders, academic subject matter experts, and non-profit organizations. First launched in 2017 and now being re-established after a pandemic-driven pause, its mission is to represent the field in addressing bottlenecks and accelerating the development of new treatments for PSP and other primary tauopathies.

Operating Details

The PSP Research Roundtable is convened by CurePSP, with Dr. Adam Boxer (Endowed Professor in Memory and Aging, University of California, San Francisco) and Dr. Mirek Brys (Vice President and Global Program Head, Novartis) serving as co-chairs. FDA and EMA participation is a critical priority for this reconvened effort, and meeting dates have been chosen specifically to ensure both agencies can attend in person. Specific priorities for the Roundtable will be defined by a consensus-driven industry steering committee, with input from the organizing committee.

The reconvened Roundtable will meet in Washington, DC, on Thursday, October 22 and Friday, October 23, 2026. Topics will be prioritized by the Steering Committee and may include clinical outcome measures, biomarkers, earlier and more precise diagnosis, emerging digital assessment approaches and best practices in patient management.

Attendance is by invitation only. Researchers, academic experts and decision makers from key regulatory agencies including the FDA and EMA will participate alongside member companies. The initiative is designed to enable ongoing dialogue with regulators and to generate consensus-driven outputs, including publications intended to help guide the field.

The outcomes of the PSP Research Roundtable are expected to facilitate clinical trials in PSP and to develop new guidelines for outcome measures that are meaningful and acceptable to regulatory bodies.

Becoming a Member

Membership in the PSP Research Roundtable is by invite only. We encourage leaders in the pharmaceutical, imaging and diagnostics industry who are interested in advancing the science of PSP and related tauopathies.

For large pharmaceutical companies (organizations with annual global revenues exceeding $250 million), the annual membership contribution is $50,000. Participation tiers for mid-sized and emerging biotechnology companies are also available and can be discussed based on organizational scope and engagement.

Member companies will have one voting member on the Steering committee and an additional three participants at Roundtable meeting. Member company will vote on agenda priorities, participate in focused working groups and contribute to consensus-driven outputs and potential publications.

Contact

Kristophe Diaz, PhD, CurePSP, Chief Executive Officer

diaz@curepsp.org